ING Groep NV Sells 522 Shares of Edwards Lifesciences Co. (NYSE:EW)

ING Groep NV reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 0.6% during the 3rd quarter, Holdings Channel reports. The fund owned 80,565 shares of the medical research company’s stock after selling 522 shares during the period. ING Groep NV’s holdings in Edwards Lifesciences were worth $5,316,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently made changes to their positions in EW. Park Avenue Securities LLC lifted its holdings in Edwards Lifesciences by 0.5% during the 2nd quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after buying an additional 108 shares during the period. City State Bank raised its position in Edwards Lifesciences by 16.5% in the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock valued at $85,000 after buying an additional 130 shares during the last quarter. Stableford Capital II LLC increased its stake in Edwards Lifesciences by 2.7% in the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock valued at $533,000 after buying an additional 159 shares during the last quarter. Purus Wealth Management LLC boosted its stake in Edwards Lifesciences by 5.2% in the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after purchasing an additional 160 shares in the last quarter. Finally, Busey Bank raised its position in Edwards Lifesciences by 1.9% in the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock worth $816,000 after buying an additional 165 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 2.4 %

Shares of EW opened at $67.76 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $39.96 billion, a P/E ratio of 9.78, a price-to-earnings-growth ratio of 3.74 and a beta of 1.12. The company’s 50-day moving average price is $67.42 and its 200 day moving average price is $76.37. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the business posted $0.59 earnings per share. The company’s quarterly revenue was up 8.9% on a year-over-year basis. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

EW has been the subject of a number of analyst reports. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Evercore ISI dropped their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Wells Fargo & Company decreased their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Morgan Stanley restated an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Finally, Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $75.67.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,250 shares of company stock valued at $2,744,438. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.